This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: A16 (respiratory tuberculosis, not confirmed bacteriologically or histologically) | Special Copayment Reduction: V206 (Special Copayment Reduction for latent tuberculosis infection treatment: persons who are TST- or IGRA-positive and do not have active tuberculosis, among others, are eligible for registration; the copayment for covered medical care is supported for 1 year from the registration date, with extension by 6 months if needed) |
| B. Synonyms | Latent tuberculosis infection, latent tuberculosis, latent TB infection, TB infection (without disease), Tuberculosis infection |
| C. Adult onset | Likelihood of first onset in adulthood: present to a very high degree. By definition, latent tuberculosis can remain asymptomatic for life, so regardless of when the infection occurred, most cases are first diagnosed in adulthood through adult health checkups, screening before starting immunosuppressive treatment, and contact investigations; in domestic contact investigation data as well, the positivity rate is seen to increase with age (41.9% at age 70 and older). |
| 1. History | History of the development of diagnostic technology following Koch's discovery of the tubercle bacillus in 1882: tuberculin, the Pirquet and Mantoux skin tests, standardization of PPD, and development of IGRA. |
| 2. Causes | Caused by a state in which, after infection by inhalation of Mycobacterium tuberculosis droplet nuclei, host immunity does not completely eliminate the organism but only contains it. |
| 3. Genetics | NRAMP1/SLC11A1, IFN-γ and IL-12 pathway genes (MSMD), and NAT2 metabolic enzyme polymorphism are involved in susceptibility to infection and risk of adverse drug reactions. |
| 4. General epidemiology | About one quarter of the world population estimated to be infected; 38.2 per 100,000 new cases in Korea in 2023; latent tuberculosis positivity rate in contact investigations about 29.5%. |
| 5. Pathophysiology | Through bacterial proliferation within alveolar macrophages and granuloma formation by the Th1/IFN-γ immune response, the organisms are contained in a dormant state within caseous necrotic foci. |
| 6. Symptoms | By definition completely asymptomatic; on progression to active tuberculosis, cough for 2 weeks or more, hemoptysis, fever, night sweats, and weight loss appear. |
| 7. Signs | As a rule there are no specific findings on physical examination; on progression to active disease, tuberculosis-specific signs such as abnormal lung sounds and lymphadenopathy accompany. |
| 8. Screening | High-risk groups are screened with the tuberculin skin test (TST) and the interferon-gamma release assay (IGRA), and the two tests are complementary. |
| 9. Diagnosis | Latent tuberculosis is confirmed only when TST/IGRA is positive and active tuberculosis is excluded by symptoms, chest imaging, and sputum testing if needed. |
| 10. Treatment | Short-course combination regimens such as 4 months of rifampin (4R), 3 months of isoniazid + rifampin (3HR), or rifapentine (3HP) are the standard treatment. |
| 11. Prognosis | Without treatment, 5-15% progress to active tuberculosis over a lifetime; completing treatment reduces the risk of disease by about 60-90%, but adherence is the key. |
| 12. Prevention | Early treatment and infection control of index patients, expanded screening and preventive treatment of high-risk groups, contact investigation, and pediatric BCG vaccination are the key strategies. |
| 13. References | Latent tuberculosis infection: updated and consolidated guidelines for programmatic management … and 9 other papers |
The etiology of tuberculosis was identified in 1882, when Robert Koch identified Mycobacterium tuberculosis by acid-fast staining. Later, in 1890, Koch developed "Old Tuberculin (OT)" from culture filtrate; the initial attempt for therapeutic purposes failed, but its diagnostic potential was recognized, and it became the basis for the later development of skin tests. In 1907, Clemens von Pirquet devised a scarification skin test using diluted tuberculin and showed that sensitization to the tubercle bacillus could be determined through the local skin reaction, and he is known to have first used the term "latent tuberculosis" around this time.
In 1908, Albert Calmette and Alfred Wolff-Eisner independently devised a conjunctival tuberculin test, but it was not widely used because of side effects such as keratitis, and in the same year Charles Mantoux introduced intradermal injection with a fine needle, making standard-dose administration with high reproducibility possible. In the 1920s, the method of using induration of 5 mm or more at 48 hours as the positive criterion was widely accepted. In the 1930s-40s, the biochemist Florence Seibert purified the active protein component of tuberculin and established purified protein derivative (PPD), and the PPD-S standard produced in 1941 was adopted as the international standard by the World Health Organization (WHO) in 1952, forming the basis of today's tuberculin skin test (TST).
As understanding of the tubercle bacillus deepened, latent tuberculosis came to be reinterpreted not as a simple asymptomatic state but as one stage of a continuous spectrum that can progress to active tuberculosis. From the 1990s onward, the interferon-gamma release assay (IGRA), that is, the QuantiFERON-TB Gold and T-SPOT.TB family of tests, using M. tuberculosis-specific antigens such as ESAT-6 and CFP-10 that are absent from BCG vaccine strains and most nontuberculous mycobacteria, was developed, largely compensating for the BCG cross-reactivity and interobserver variability problems of the TST.
In terms of treatment as well, after the 6- to 12-month isoniazid monotherapy regimen became the standard in the 1950s-60s, there was no major change for nearly half a century, but with the publication in 2011 in the United States of the clinical efficacy of the 3-month once-weekly isoniazid-rifapentine combination regimen (3HP) and the successive validation of short rifampin-based regimens from 2018 onward, the paradigm of preventive treatment shifted from "long-term monotherapy" to "short-course combination and rifampin-based regimens." Since 2015, as part of the End TB Strategy, the WHO has elevated management of latent tuberculosis to a key pillar for reducing the occurrence of new cases, and after publishing the consolidated guidelines on latent tuberculosis infection in 2018, it has concretized strategies for expanding testing and treatment centered on high-risk groups through revisions in 2020 and 2024.
In Korea, since the publication of the first national tuberculosis clinical guidelines in 2011, recommendations for the diagnosis and treatment of latent tuberculosis have been continuously refined to match international trends and domestic epidemiology through revisions in 2014, 2020, and 2024 (5th edition), and the legislation of latent tuberculosis screening for workers in congregate facilities and others through the 2017 amendment of the Tuberculosis Prevention Act was also an important turning point in the history of domestic management.
The causative pathogen of latent tuberculosis infection is Mycobacterium tuberculosis, and rarely it can also be caused by other species belonging to the M. tuberculosis complex, such as M. bovis and M. africanum. The route of infection is virtually only airborne transmission through droplet nuclei (diameter about 1-5 μm) released by patients with active pulmonary or laryngeal tuberculosis when coughing, sneezing, or talking; whereas large droplets settle quickly, droplet nuclei remain suspended in the air for a long time, greatly increasing the risk of transmission in enclosed, poorly ventilated spaces.
Inhaled organisms reach the alveoli and are phagocytosed by alveolar macrophages; at this point, when the host's innate and adaptive immunity reach a balance in which they do not completely eliminate bacterial proliferation but suppress it enough to prevent systemic dissemination and tissue destruction, latent infection results. That is, latent tuberculosis is not a disease with a separate pathogen or an independent route of infection, but a result of the host-pathogen interaction to the same M. tuberculosis infection, meaning an immunologically controlled state that does not progress immediately to active tuberculosis. Factors affecting the establishment of infection include the infectiousness of the index patient (smear positivity, presence of cavitary lesions, frequency of coughing), intensity and cumulative duration of exposure, environmental factors such as room size and ventilation rate, and the immune status of the exposed person.
The WHO explains that among people exposed to the tubercle bacillus, a considerable number are cleared without infection (early clearance), some become infected and shift to a latent state, and a minority progress directly to active disease (primary progressive tuberculosis). The fundamental difference from active tuberculosis is that latent tuberculosis itself is not infectious. Because the organisms exist in a metabolically low-activity state (dormancy) within granulomas, no shedding of organisms in sputum or transmission to others occurs. However, when the host-pathogen balance is broken by immunosuppression, aging, comorbidities, and so on, the same pathogen can reactivate and cause active tuberculosis, and with advances in molecular epidemiologic genotyping techniques, it has been confirmed that in high-burden countries, in addition to endogenous reactivation of past infection, exogenous reinfection due to repeated exposure also accounts for a considerable proportion. Therefore, the recent view is to understand latent and active tuberculosis etiologically as different phases of one continuous spectrum of infection, and when addressing the "cause" of latent tuberculosis, it is clinically valid to approach it within the framework of the interaction between pathogen exposure and the host immune response rather than the pathogen itself.
Evidence has accumulated that, in addition to pathogen factors, the host's genetic background is substantially involved in the establishment of latent tuberculosis infection and its progression to active tuberculosis. Notably, polymorphisms of the NRAMP1 (SLC11A1) gene, which is involved in divalent cation (iron, manganese) transport in macrophages, showed a significant association with tuberculosis susceptibility in a study of West African populations (Bellamy et al., NEJM 1998), and in subsequent meta-analyses including multiple populations, it has been repeatedly confirmed that specific alleles are associated with increased risk of tuberculosis.
The IFN-γ/IL-12 axis is the key pathway regulating the antimycobacterial killing capacity of macrophages, and rare monogenic defects in related genes such as the IFN-γ receptor (IFNGR1/2), IL-12 receptor (IL12RB1), STAT1, and NEMO cause a clinical syndrome called "Mendelian Susceptibility to Mycobacterial Disease (MSMD)," showing severe, disseminated susceptibility to mycobacterial infections, including BCG and nontuberculous mycobacteria. This is representative genetic evidence supporting that cellular immunity, especially the Th1 pathway, is essential for suppressing the tubercle bacillus. In addition, HLA class II alleles, Toll-like receptor (TLR2, TLR4) polymorphisms, TNF-α promoter polymorphisms, and vitamin D receptor (VDR) gene variants have also been reported to be associated with tuberculosis susceptibility or the risk of progression from latent infection to active tuberculosis, but because results differ by population from study to study, it is understood as a multifactorial trait rather than explained by a single gene. Twin studies also support the existence of genetic predisposition, showing a higher concordance rate of tuberculosis in monozygotic twins than in dizygotic twins.
Of more direct clinical significance are the gene polymorphisms involved in the metabolism of preventive treatment drugs. Isoniazid is metabolized by hepatic N-acetyltransferase 2 (NAT2), and many meta-analyses have reported that patients with the NAT2 slow acetylator genotype maintain high blood concentrations of isoniazid and its metabolites and have a significantly increased risk of drug-induced hepatotoxicity; it should also be recognized in clinical practice that the frequency of the slow acetylator genotype differs greatly by ethnicity. However, these susceptibility-related genetic variants generally only modestly increase relative risk, and genetic testing is currently not routinely used in clinical practice to decide on latent tuberculosis screening or treatment. Studies are under way to genetically stratify groups at high risk of reactivation and groups at high risk of adverse drug reactions through the accumulation of genome-wide association study (GWAS) and polygenic risk score research, and this is expected to contribute to the development of personalized preventive treatment strategies in the future.
According to the World Health Organization (WHO) and related epidemiologic estimates, about one quarter (about 23-25%) of the world's population is estimated to be infected with the tubercle bacillus and in a latent tuberculosis state. As of 2023, about 10.8 million people worldwide newly developed active tuberculosis and about 1.25 million died of tuberculosis, and tuberculosis returned to the top spot as the leading cause of death from a single infectious disease worldwide after the COVID-19 pandemic period (WHO Global Tuberculosis Report 2024). The prevalence of latent tuberculosis and the incidence of tuberculosis differ greatly by region; in high-burden countries such as India and sub-Saharan Africa the incidence exceeds 300 per 100,000 population, whereas in low-burden countries such as the United States it is low, below 100. By sex, the incidence is reported to be higher in men than in women (e.g., US data: 31.8 per 100,000 in men versus 20.1 in women), and about 12% of new cases worldwide occur in people with HIV coinfection.
Regarding the occurrence of new tuberculosis cases in Korea, a total of 19,540 cases were reported in 2023, recording an incidence of 38.2 per 100,000 population, a decrease of 4.1% from 2022. Since 2011, when the national tuberculosis control program began in earnest, the incidence has declined by about 7.6% per year on average, for a cumulative decrease of 61.3%, but in those aged 65 and older the incidence is still high at 119.5 per 100,000 population and has recently even increased slightly, so the management burden due to population aging is growing. In terms of latent tuberculosis, in the 2024 KDCA contact investigation, 105,989 household and congregate-facility contacts were investigated, and among the 59,547 close contacts who were tested, 17,537 (about 29.5%) were diagnosed with latent tuberculosis infection (household contacts 30.1%, facility contacts 29.2%). The positivity rate increased with age, reaching 41.9% at age 70 and older, but the actual treatment initiation rate was conversely lower with older age (17.2% at age 70 and older), so the gap between diagnosis and treatment was prominent in the elderly. Among those who started treatment, about 60% completed treatment, and about 11% discontinued treatment for reasons such as adverse effects, development of tuberculosis, or death.
Thus, although the incidence of new tuberculosis cases in Korea continues to decline, it is still known to be among the highest of OECD member countries, so the national latent tuberculosis screening and treatment program for suppressing new cases is operated as a key pillar of the comprehensive tuberculosis control plan. The WHO's End TB Strategy sets the goal of reducing the tuberculosis incidence by 90% and the mortality by 95% by 2035 compared with 2015, and several modeling studies have emphasized that achieving this goal is not possible with treatment of active tuberculosis alone and that large-scale expansion of latent tuberculosis screening and preventive treatment is essential. Korea's comprehensive tuberculosis control plan also sets a target for reducing the incidence of new cases in line with these international goals, and manages expansion of contact investigation and improvement of the latent tuberculosis treatment rate in high-risk groups as detailed implementation indicators.
When droplet nuclei containing the tubercle bacillus are inhaled, the organisms reach the alveoli and are phagocytosed by alveolar macrophages. Macrophages attempt to destroy the organisms, but M. tuberculosis has the ability to survive intracellularly through various mechanisms such as inhibition of phagosome-lysosome fusion and damage to the phagosomal membrane via the ESX-1 secretion system, so it is common for the organisms not to be completely eliminated by initial phagocytosis alone. At the local site of infection, dendritic cells carry bacterial antigens to the regional lymph nodes where antigen presentation occurs, and thereafter, over about 2-8 weeks, an antigen-specific cellular immune response centered on CD4+ Th1 cells is established (this period generally coincides with the window period required for TST/IGRA conversion). IFN-γ secreted by Th1 cells acts as a key signal that activates macrophages and suppresses bacterial proliferation through the generation of reactive oxygen and nitrogen intermediates and the induction of autophagy, and TNF-α is essential for the structural maintenance of granulomas.
In this process, a granuloma, in which macrophages, epithelioid cells, Langhans giant cells, and lymphocytes are organized concentrically, forms at the site of infection, and when the primary focus (Ghon focus) and regional lymph node lesions are observed together, it is referred to as the Ghon complex (Ranke complex). The center of the granuloma often progresses to caseous necrosis in a hypoxic, low-pH, nutrient-deprived environment, and this microenvironment converts the tubercle bacillus to a metabolically low-activity state (dormancy), allowing it to evade immune surveillance while surviving for a long period without being completely killed. Recent studies reinterpret the granuloma not as a simple defensive barrier but as a dynamic structure in which the pathogen and host immunity continuously interact, and it has been confirmed that bacterial burden and immune status can differ from lesion to lesion even within the same individual (spatial heterogeneity).
Latent tuberculosis is thus an unstable equilibrium between the organism and host immunity, and when cellular immunity is reduced by HIV infection, use of biologics such as tumor necrosis factor inhibitors, chronic renal failure, diabetes, old age, malnutrition, smoking, and so on, the structural integrity of the granuloma collapses, caseous material liquefies, and the organisms re-proliferate and are discharged into adjacent airways, so that reactivation can occur as active tuberculosis accompanied by cavity formation and endobronchial dissemination. The cumulative lifetime risk of progression to active tuberculosis after exposure is estimated at about 5-15%, a considerable proportion of which occurs within the first 2 years after infection, while the rest can manifest after a latency of several decades. Recent studies using imaging and single-cell analysis techniques have revealed that even within a single individual, some granulomas become completely calcified and fibrotic with death of the organisms while others remain active, showing heterogeneous courses among lesions, which provides evidence that latent tuberculosis should be understood not as a single static state but as a collection of dynamic processes progressing at different rates in each lesion.
Because latent tuberculosis infection is by definition "a state in which only an immunological response to M. tuberculosis is present without clinical evidence of active disease," it is not itself accompanied by any subjective symptoms. It can be classified as latent tuberculosis only when there are no clinical symptoms suggestive of tuberculosis, such as fever, cough, sputum, weight loss, night sweats, or generalized weakness, and this asymptomatic nature is the key feature that defines latent tuberculosis. Therefore, patients with latent tuberculosis almost never recognize symptoms themselves and visit a medical institution; most are found through active screening such as contact investigation, pre-employment and periodic health checkups, screening before starting immunosuppressive treatment, and the national tuberculosis screening program. The clinically important implication is that infection with the tubercle bacillus should not be ruled out simply because there are no symptoms, and that, rather, the asymptomatic state itself is the normal clinical picture of latent tuberculosis, so active screening of high-risk groups should be prioritized. Recently, the concept of 'subclinical or incipient tuberculosis,' in which there are mild radiologic or microbiologic abnormalities between latent tuberculosis and typical active tuberculosis but typical symptoms are not yet present, has been proposed, and a view of understanding it as a continuous spectrum running from asymptomatic to mild abnormality to full active disease is also spreading.
From the moment latent tuberculosis progresses to active tuberculosis, the clinical picture is completely different. Typical tuberculosis symptoms may appear, such as cough lasting 2 weeks or more, sputum, hemoptysis, chest pain, dyspnea, low-grade fever or fever that worsens in the afternoon, night sweats, loss of appetite, unintentional weight loss, and generalized fatigue, and caution is needed because in children or the elderly these typical symptoms may not be evident and may appear in atypical forms such as failure to thrive and nonspecific lethargy. When it progresses to extrapulmonary tuberculosis, a wide variety of clinical pictures can occur depending on the organ involved, such as lymphadenopathy, chest pain due to pleural effusion, back pain due to spinal tuberculosis, and headache and altered consciousness due to tuberculous meningitis. The clinician should check at every visit for new onset of such symptoms suggestive of active tuberculosis in patients identified as having latent tuberculosis who are being treated or followed, and before starting preventive treatment it is clinically very important to always check for symptoms suggestive of active tuberculosis to prevent preventive therapy composed of insufficient drugs from being given to a patient who actually has active tuberculosis. Meanwhile, even if physically asymptomatic, the diagnosis of tubercle bacillus infection itself can cause considerable psychological burden for the patient (anxiety about stigma, fear of future onset, reluctance toward long-term medication), so it is desirable for the clinician, at the diagnostic consultation, to explain both the natural course of the disease and the benefits of preventive treatment to reduce unnecessary anxiety and improve treatment adherence.
In principle, patients with latent tuberculosis infection show no specific abnormal findings related to tuberculosis on physical examination. Routine examination, including vital signs, chest auscultation, and lymph node palpation, shows normal findings, and on plain chest radiography the findings are often normal without active lesions or show only inactive findings, such as fibrocalcific nodules judged to be traces of past infection, old apical scarring, and calcified lymph nodes (Ghon focus, Ranke complex). Such old radiographic traces suggest past infection and are not evidence of current active disease, but as naturally healed lesions they are classified as a group with a higher risk of future reactivation than the general population and are often targets for treatment (the domestic guidelines also specify naturally healed tuberculosis scars as a target of strong treatment recommendation).
In contrast, when it progresses to active tuberculosis, various signs may appear on physical examination. In pulmonary tuberculosis, localized crackles or bronchial breath sounds over the lesion, amphoric breath sounds in advanced cavitary lesions, dullness to percussion and decreased breath sounds when accompanied by pleural effusion, weight loss and cachexia accompanying a chronic wasting disease, and clubbing in chronic progression may be observed. When it progresses to disseminated (miliary) tuberculosis, findings of systemic involvement such as hepatosplenomegaly and choroidal tubercles on fundus examination may accompany, so it should be considered in the differential diagnosis in patients with fever of unknown origin. In extrapulmonary tuberculosis, painless lymphadenopathy and fistula formation in cervical lymph node tuberculosis, kyphotic deformity of the spine and local tenderness in spinal tuberculosis (Pott disease), neck stiffness and focal neurological signs in tuberculous meningitis, pericardial friction rub or elevated jugular venous pressure in tuberculous pericarditis, and sterile pyuria in genitourinary tuberculosis may appear characteristically.
The clinician should recognize that confirming the complete absence of such signs of active tuberculosis when examining a patient with latent tuberculosis is an essential procedure before starting preventive treatment, and if a new abnormal physical finding is found during follow-up, reevaluation for active tuberculosis, including chest imaging and sputum testing, should be performed immediately. In children, checking for the presence and form of a BCG vaccination scar can be a reference for confirming vaccination history and reading the TST, but it should also be noted that vaccination or infection cannot be determined by the presence of a scar alone.
The tests that form the basis of latent tuberculosis screening are the tuberculin skin test (TST) and the interferon-gamma release assay (IGRA), and both tests share the fundamental limitation that, to date, there is no perfect standard test (gold standard) that distinguishes infection from active disease. The TST measures the size of induration 48-72 hours after intradermal injection of purified protein derivative (PPD) into the forearm; it has the advantages of low cost and being performable without separate equipment, but has disadvantages such as false positives due to BCG vaccination history or exposure to nontuberculous mycobacteria, false negatives in immunocompromised states, interobserver variability, decreased adherence due to the need for a return visit, and difficulty of interpretation owing to the booster phenomenon on repeat testing.
The domestic guidelines allow either TST or IGRA in immunocompetent adults who received a single BCG vaccination in infancy, but recommend IGRA alone to avoid false positives when BCG was given repeatedly or an additional dose was received in adulthood. The usual TST positivity criterion is induration of 10 mm or more, and in immunocompromised persons such as those with HIV infection, 5 mm or more is judged positive. IGRA stimulates the specimen with specific antigens such as ESAT-6 and CFP-10, which are present in the tubercle bacillus but absent from BCG vaccine strains and most nontuberculous mycobacteria, and either quantifies IFN-γ secreted from T cells (QuantiFERON-TB Gold Plus, etc.) or counts IFN-γ-secreting T cells (T-SPOT.TB); it has the advantages of high specificity because it is unaffected by BCG vaccination history, being performable with a single blood draw, and having no booster effect. QuantiFERON-TB Gold Plus is usually judged positive at 0.35 IU/mL or more, and results in the borderline range close to this (roughly 0.35-0.7 IU/mL) may change on retesting, so caution is needed in interpretation.
In immunocompromised adults, according to the domestic guidelines, IGRA is performed first, and adding a TST if it is negative or performing both tests simultaneously is also allowed. Both tests should be used only to screen for infection and not to diagnose active tuberculosis, and plain chest radiography must be performed together as a complementary means of evaluating for active lesions regardless of the screening test result. The WHO recommends that in contact investigations, for children under 5 years and people with HIV, TST/IGRA results need not necessarily be required before starting preventive treatment, suggesting that in resource-limited settings risk-based clinical judgment may take precedence over test results.
Diagnosis of latent tuberculosis consists of two steps: (1) confirming immunological evidence of tubercle bacillus infection through TST or IGRA and (2) excluding active tuberculosis. First, ask the subject about clinical symptoms suggestive of tuberculosis (cough for 2 weeks or more, hemoptysis, fever, night sweats, weight loss, etc.) and perform plain chest radiography to assess for active lesions. If there are no symptoms and the chest imaging is normal or shows only inactive findings (old fibrosis, calcified nodules, etc.), latent tuberculosis can be diagnosed and treatment can proceed without additional microbiologic testing.
However, if there are symptoms or findings on chest imaging suggestive of active tuberculosis (cavity, infiltrate, pleural effusion, etc.), acid-fast bacilli smear, mycobacterial culture, and nucleic acid amplification testing (Xpert MTB/RIF, etc.) must be performed on sputum (preferably 2-3 specimens collected after waking early in the morning), and latent tuberculosis treatment can be started only after active tuberculosis has been excluded. This is a clinically very important procedure because there is a risk of emergence of resistant organisms if a latent tuberculosis preventive regimen composed of insufficient drugs is given to a patient with active tuberculosis. If the initial test in a contact investigation is negative, retesting at 8-10 weeks after the initial exposure is recommended, taking into account the incubation period needed for infection to be established (about 8-10 weeks), and if the TST induration increases by 10 mm or more between the two time points or the IGRA converts from negative to positive, it is judged to be new infection (conversion).
The TST and IGRA should be understood not as interchangeable tests but as complementary tests chosen or used sequentially according to clinical context; neither test can distinguish recent from past infection, and neither can be used to judge treatment response or cure (repeat TST/IGRA testing as follow-up after treatment is not routinely recommended). For the differential diagnosis, fungal infections that can show imaging findings similar to pulmonary tuberculosis (histoplasmosis, etc.), nontuberculous mycobacterial lung disease, sarcoidosis, and lung cancer should be considered, and especially for nodular lesions found incidentally on chest imaging, differentiation between tuberculoma and malignancy may be needed. Recently, transcriptome-based biomarker research has been under way to distinguish, within latent tuberculosis, subtypes at high risk of reactivation (subclinical or incipient TB), but a validated test that can be used routinely in clinical practice has not yet been established. In addition, IGRA reversion from positive to negative over time and fluctuation of results near the borderline range are not uncommonly observed, so rather than mechanically determining infection from the result of a single test, clinical interpretation based on pretest probability that integrates exposure history, risk group status, and consistency on repeat testing is required.
The goal of latent tuberculosis treatment (tuberculosis preventive treatment) is to eliminate organisms latent in the body and block future progression to active tuberculosis. The WHO and the US National Tuberculosis Controllers Association (NTCA)/CDC have both shifted their guidelines toward preferentially recommending short-course regimens that include rifamycin-class drugs. Representative treatment regimens are as follows. ① 4 months of daily rifampin alone (4R, adults 10 mg/kg, maximum 600 mg/day) — strongly recommended in HIV-negative persons. ② 3 months of daily isoniazid + rifampin combination (3HR, isoniazid 300 mg + rifampin 600 mg/day) — recommended for all ages, including people with HIV. ③ 3 months of once-weekly isoniazid + rifapentine combination (3HP, for adults isoniazid 900 mg + rifapentine 900 mg, 12 doses in total) — strongly recommended, including for children aged 2 years and older and people with HIV; in US clinical studies it was shown to have efficacy equivalent to the standard 9-month isoniazid regimen without greater toxicity, and both directly observed therapy (DOT) and self-administered therapy are allowed. ④ 9 months (or 6 months) of daily isoniazid alone (9H/6H, 5 mg/kg, maximum 300 mg/day) — an alternative when rifamycin-class drugs are contraindicated or poorly tolerated.
The domestic guidelines also present 4R and 3HR as preferred regimens and 9H as an alternative when rifampin is difficult to use. The rationale for favoring shorter regimens rests on the results of many comparative studies and Cochrane systematic reviews showing that the shorter the regimen duration, the higher the treatment completion rate, and that hepatotoxicity is similar or lower compared with 9-month isoniazid monotherapy. When the index patient was exposed to organisms resistant to isoniazid or rifampin, an individualized regimen (e.g., a fluoroquinolone-based regimen) should be considered according to the index patient's drug susceptibility results.
During treatment, adverse reactions such as hepatotoxicity symptoms (jaundice, nausea, right upper quadrant pain, etc.), rash, and peripheral neuropathy should be monitored through monthly clinical evaluation, and in groups at high risk of hepatotoxicity, such as those with underlying liver disease, chronic alcohol use, hepatitis B coinfection, old age, HIV infection, and pregnancy, periodic liver function tests are needed before and during treatment. When isoniazid is used, pyridoxine (vitamin B6) is co-administered to prevent peripheral neuropathy in pregnant women and in patients with diabetes, chronic kidney disease, malnutrition, or alcohol misuse. Because rifampin/rifapentine interact with many drugs (especially anticoagulants, some antiretrovirals, and oral contraceptives), review of concomitant medications is essential. In pregnant women, unless the risk of active tuberculosis is particularly high, postponing treatment until after delivery can usually be considered, but in high-risk pregnant women such as those with HIV infection, treatment is given even during pregnancy, and in children, dose adjustment by body weight and management of medication adherence through caregivers are especially important. In patients with decreased renal function, rifampin needs no dose adjustment, but isoniazid may need adjustment in consideration of accumulation of nephrotoxic metabolites.
The lifetime risk of developing active tuberculosis in untreated persons with latent tuberculosis infection is estimated at about 5-15% (also reported as 5-10% depending on the source), and this risk is not uniform: it is highest within the first 1-2 years after infection and then gradually declines. According to US data, reactivation of untreated latent tuberculosis is estimated to account for about 80% of all new tuberculosis cases, showing that the contribution of preventive treatment to suppressing new cases is very large. However, when risk factors such as HIV coinfection, recent infection (within 2 years), age under 5 years, use of immunosuppressants (especially anti-TNF agents, high-dose steroids), end-stage renal disease on dialysis, silicosis, organ or hematopoietic stem cell transplantation, diabetes, low body weight (less than 90% of ideal weight), head and neck cancer or lung cancer, leukemia, and smoking and alcohol abuse accompany, the annual incidence can rise several-fold to several tens of fold, so the prognosis varies greatly depending on the presence of accompanying risk factors. In particular, in people with HIV, the annual risk of onset without treatment reaches about 10%, reported to be equal to the lifetime risk in HIV-negative persons.
When preventive treatment is completed, the risk of progression to active tuberculosis is reported to be reduced by about 60-90% depending on the literature (the CDC presents the preventive effect of appropriately completed treatment as about 90%), and there are long-term follow-up results that this preventive effect can persist for up to 19 years after treatment ends. However, this conversely means that in the majority of low-risk persons receiving preventive treatment, infection that would not have developed in the first place is treated while bearing only the risk of adverse drug reactions, so clinical judgment that considers both the individual's risk of onset and the risk of drug side effects before starting treatment is needed. If treatment is abandoned midway or not completed, the preventive effect cannot be expected, and domestic data also show that only about 60% of those who started treatment reach completion and about 11% discontinue because of adverse effects, onset, death, and so on, showing that adherence is an important variable determining actual prognosis.
Once it has progressed to active tuberculosis, the prognosis is that most cases can be cured with appropriate standard antituberculosis chemotherapy (2HRZE/4HR, etc.), but morbidity and mortality increase significantly with diagnostic delay, multidrug-resistant tuberculosis, accompanying immunocompromise, and extrapulmonary or disseminated tuberculosis. Therefore, appropriately screening at the latent tuberculosis stage and having treatment completed is evaluated as the most effective strategy for preventing an individual's tuberculosis morbidity and blocking community transmission. Recently, predictive model studies are also under way that go beyond dichotomizing risk groups by exposure history or comorbidities alone and combine the quantitative IGRA value, chest imaging findings, and clinical risk factors to score individual risk of onset, which is expected to improve the precision of prognosis prediction in the future.
Prevention strategies for latent tuberculosis can be broadly divided into (1) blocking exposure and vaccination to prevent initial infection itself and (2) preventive treatment (latent tuberculosis treatment) that identifies already infected high-risk groups and prevents progression to active tuberculosis. In terms of blocking infection, early diagnosis and prompt start of treatment of patients with active pulmonary tuberculosis is the most effective way to block transmission, and in medical institutions and congregate facilities, a three-tier infection control hierarchy consisting of administrative measures (early patient screening and isolation protocols), environmental measures (negative-pressure isolation rooms, ventilation, and ultraviolet germicidal irradiation, etc.), and personal protective equipment (wearing respiratory protection such as N95) should be applied. The BCG vaccine has a proven effect in preventing severe tuberculosis in children (tuberculous meningitis, disseminated tuberculosis), but its effect in preventing adult pulmonary tuberculosis or latent infection itself is limited, so many countries including Korea maintain vaccination of infants and young children but do not make it the core of an adult vaccination strategy, and clinical trials of new tuberculosis vaccines for adolescents and adults (M72/AS01E, etc.) are currently under way.
In terms of latent tuberculosis preventive treatment, the WHO recommends that people with HIV, household contacts of tuberculosis patients under 5 years of age, those scheduled for anti-TNF therapy, dialysis patients, organ or hematopoietic stem cell transplant candidates, and silicosis patients be prioritized for testing and treatment in all countries, and that prisoners, health care workers, migrants from high-burden countries, homeless people, and drug users be considered selectively in low-burden countries. In addition, the domestic guidelines specify people with naturally healed tuberculosis scars, patients with autoimmune diseases on long-term steroids, end-stage renal disease patients on dialysis, patients with hematologic malignancies, and health care workers as targets of the recommendation.
At the level of the national tuberculosis control program, active case finding through contact investigation, periodic screening of congregate facilities (schools, nursing facilities, correctional facilities, etc.), and recruitment and periodic screening of health care workers operate as the key means, and providing short-duration regimens (3HP, 3HR, 4R) preferentially to diagnosed persons with latent tuberculosis infection, together with adherence-improving strategies such as medication counseling by case managers, adverse effect monitoring, and peer support, is important for raising the treatment completion rate.
In addition, reducing the risk of re-exposure through continuous education of patients receiving latent tuberculosis treatment and their contacts determines the practical success or failure of the prevention strategy, and the WHO has set interim and long-term milestones of a 50% reduction in tuberculosis incidence by 2025 and a 90% reduction by 2035 compared with 2015, encouraging each country to strengthen latent tuberculosis management.
World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: World Health Organization; 2018. who.int
Sterling TR, Njie G, Zenner D, Cohn DL, Reves R, Ahmed A, et al. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep. 2020;69(1):1-11. DOI: 10.15585/mmwr.rr6901a1. PMID: 32053584.
Adigun R, Singh R. Latent Tuberculosis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. NCBI Bookshelf ID: NBK599527. NBK599527
Korean Academy of Tuberculosis and Respiratory Diseases, Joint Committee for the Korean Guidelines for Tuberculosis. Diagnosis and Treatment of Latent Tuberculosis Infection in Adults in South Korea. Tuberc Respir Dis (Seoul). 2024. DOI: 10.4046/trd.2024.0122. PMID: 39374926.
World Health Organization. Global Tuberculosis Report 2024. Geneva: World Health Organization; 2024. who.int
Institute of Medicine (US) Committee on Regulating Occupational Exposure to Tuberculosis. The Tuberculin Skin Test. In: Tuberculosis in the Workplace. Washington (DC): National Academies Press (US); 2001. NCBI Bookshelf ID: NBK222464. NBK222464
Bellamy R, Ruwende C, Corrah T, McAdam KP, Whittle HC, Hill AV. Variations in the NRAMP1 gene and susceptibility to tuberculosis in West Africans. N Engl J Med. 1998;338(10):640-644. DOI: 10.1056/NEJM199803053381002. PMID: 9486992.
Sharma SK, Sharma A, Kadhiravan T, Tharyan P. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Cochrane Database Syst Rev. 2013;(7):CD007545. DOI: 10.1002/14651858.CD007545.pub2. PMID: 23828580.
Korea Disease Control and Prevention Agency. Results of the 2024 tuberculosis epidemiologic investigation of family and congregate-facility contacts. Public Health Weekly Report. 2025;18(39). DOI: 10.56786/PHWR.2025.18.39.1.
Ramakrishnan L. Revisiting the role of the granuloma in tuberculosis. Nat Rev Immunol. 2012;12(5):352-366. DOI: 10.1038/nri3211. PMID: 22517424.